281 related articles for article (PubMed ID: 36866958)
41. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
Hizal M; Bilgin B; Paksoy N; Kılıçkap S; Atcı MM; Kahraman S; Keskinkılıç M; Bilgetekin İ; Ayhan M; Tural D; Eren Ö; Akkoç Mustafayev FN; Yaman Ş; Tatlı AM; Bayram E; Kutlu Y; Ertürk İ; Özcan E; Gülmez A; Korkmaz M; Akagündüz B; Erdem D; Telli TA; Aksoy A; Üskent N; İriağaç Y; Baytemür NK; Aydın D; Şakalar T; Arak H; Selçukbiricik F; Ergün Y; Korkmaz T; Ak N; Ünal Ç; Akdeniz N; Özgün MA; Öksüzoğlu B; Yalçın B; Öztop İ; Algın E; Sakin A; Aydıner A; Yumuk PF; Şendur MAN
Future Oncol; 2022 Jul; 18(23):2573-2582. PubMed ID: 35734870
[TBL] [Abstract][Full Text] [Related]
42. Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis.
Liu G; Lam VK
Adv Ther; 2023 Oct; 40(10):4117-4126. PubMed ID: 37573276
[TBL] [Abstract][Full Text] [Related]
43. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
Girard N; Galland-Girodet S; Avrillon V; Besse B; Duruisseaux M; Cadranel J; Otto J; Prevost A; Roch B; Bennouna J; Bouledrak K; Coudurier M; Egenod T; Lamy R; Ricordel C; Moro-Sibilot D; Odier L; Tillon-Strozyk J; Zalcman G; Missy P; Westeel V; Baldacci S
ESMO Open; 2022 Apr; 7(2):100418. PubMed ID: 35227966
[TBL] [Abstract][Full Text] [Related]
44. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D
Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529
[TBL] [Abstract][Full Text] [Related]
45. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Lee PH; Chen KC; Hsu KH; Huang YH; Tseng JS; Yang TY; Chang GC
Anticancer Drugs; 2021 Nov; 32(10):1099-1104. PubMed ID: 34232936
[TBL] [Abstract][Full Text] [Related]
46. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
47. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Ma X; Yang S; Zhang K; Xu J; Lv P; Gao H; Qin H; Wang H; Liu X
Thorac Cancer; 2022 Jun; 13(12):1788-1794. PubMed ID: 35560808
[TBL] [Abstract][Full Text] [Related]
49. Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.
Makimoto G; Kawakado K; Nakanishi M; Tamura T; Kuyama S
Case Rep Oncol; 2021; 14(1):197-201. PubMed ID: 33776703
[TBL] [Abstract][Full Text] [Related]
50. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.
Bernabé-Caro R; Garrido P; García-Campelo R; Palmero R; Artal Á; Bayona C; Rodríguez-Abreu D; López-Brea M; Paredes A; Vicente D; Sánchez Torres JM; Majem M; Diz P; Gordo R; Coca M; de Castro J
Oncotarget; 2022; 13():812-827. PubMed ID: 35720977
[TBL] [Abstract][Full Text] [Related]
51. Lorlatinib as a treatment for ALK-positive lung cancer.
Baba K; Goto Y
Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
[TBL] [Abstract][Full Text] [Related]
52. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
Schmid S; Cheng S; Chotai S; Garcia M; Zhan L; Hueniken K; Balaratnam K; Khan K; Patel D; Grant B; Raptis R; Brown MC; Xu W; Moriarty P; Shepherd FA; Sacher AG; Leighl NB; Bradbury PA; Liu G
Clin Lung Cancer; 2023 Jan; 24(1):40-50. PubMed ID: 36270866
[TBL] [Abstract][Full Text] [Related]
53. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
Hizal M; Bilgin B; Paksoy N; Atcı MM; Kahraman S; Kılıçkap S; Güven DC; Keskinkılıç M; Ayhan M; Eren Ö; Mustafayev FNA; Yaman Ş; Bayram E; Ertürk İ; Özcan E; Korkmaz M; Akagündüz B; Erdem D; Telli TA; Aksoy A; Üskent N; Baytemür NK; Gülmez A; Aydın D; Şakalar T; Arak H; Tatlı AM; Ergün Y; Ak N; Ünal Ç; Özgün MA; Yalçın B; Öztop İ; Algın E; Sakin A; Aydıner A; Yumuk PF; Şendur MAN
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4141-4148. PubMed ID: 36048274
[TBL] [Abstract][Full Text] [Related]
54. Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Sisi M; Fusaroli M; De Giglio A; Facchinetti F; Ardizzoni A; Raschi E; Gelsomino F
Target Oncol; 2022 Jan; 17(1):43-51. PubMed ID: 35025076
[TBL] [Abstract][Full Text] [Related]
55. A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Sun S; Pithavala YK; Martini JF; Chen J
J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
[TBL] [Abstract][Full Text] [Related]
57. Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.
Taniguchi H; Akagi K; Dotsu Y; Yamada T; Ono S; Imamura E; Gyotoku H; Takemoto S; Yamaguchi H; Sen T; Yano S; Mukae H
Cancer Sci; 2023 Jan; 114(1):164-173. PubMed ID: 36086904
[TBL] [Abstract][Full Text] [Related]
58. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
Dagogo-Jack I; Oxnard GR; Evangelist M; Digumarthy SR; Lin JJ; Gainor JF; Murphy JF; Rabin MS; Heist RS; Muzikansky A; Shaw AT
JCO Precis Oncol; 2022 May; 6():e2100522. PubMed ID: 35584349
[TBL] [Abstract][Full Text] [Related]
59. Later-Line Treatment with Lorlatinib in
Hochmair MJ; Fabikan H; Illini O; Weinlinger C; Setinek U; Krenbek D; Prosch H; Rauter M; Schumacher M; Wöll E; Wass R; Brehm E; Absenger G; Bundalo T; Errhalt P; Urban M; Valipour A
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33171712
[TBL] [Abstract][Full Text] [Related]
60. Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.
Dziadziuszko R; Peters S; Ruf T; Cardona A; Guerini E; Kurtsikidze N; Smoljanovic V; Planchard D
ESMO Open; 2022 Dec; 7(6):100612. PubMed ID: 36375271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]